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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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ABSTRACT 
 
Objective: The aim of this study was to assess the efficacy of lornoxicam (LNX) in the treatment of acute migraine 
attacks. Material and Methods: This prospective, randomized, double-blind, placebo-controlled trial was conducted 
administering either LNX or placebo to patients who were diagnosed with migraine without aura according to the 
International Headache Society (the year 2004) criteria between 2010 and 2012 Results: Of 44 patients with 120 
migraine attacks, 38 were female and rest were males. Mean age was 37.75 ± 9.28 years. Patients recorded using 
LNX in 87 migraine attacks and placebo in 33 migraine attacks, respectively. Pain intensity scores of the patients were 
found similar between LNX and placebo groups, statistically. Conclusion: Although oral LNX was found to have efficacy 
similar to placebo statistically in the treatment of acute migraine attacks, further studies are needed to evaluate 
appropriately the efficacy of LNX for treatment of acute migraine attacks. 
 
Key Words:  Lornoxicam, migraine, acute attack, treatment efficacy
INTRODUCTION 
 
Migraine is a common cause of headache. Prevalence 
of migraine is reported to be 11% in the adult 
population in the studies from western countries. (1)  The 
study, which was conducted by Turkish headache 
epidemiology study group reported the incidence of 
migraine to be 16.4% between 15-65 years old. (2) It is 
seen three times more in women than men, and it often 
occurs between the ages of 25 to 55 years. (3, 4) 
Migraine treatments are generally based on two major 
groups, including non-pharmacological and pharmacol- 
ogical methods. Pharmacological treatment is divided 
into two groups; prophylactic and acute attack 
treatment.(5) Acute migraine attacks should be managed 
rapidly and effectively. Therapy is considered to be 
successful when there is decrease in the frequency and 
severity of attacks.(5) Acute attack treatment should be 
tailored to the patients systemic disease and symptoms 
as well as the severity, duration and frequency of the 
attacks. In mild and moderate attacks, non-specific 
therapy non-steroidal anti-inflammatory drugs (NSAIDs) 
alone or in combination with either caffeine or codeine 
may be used. Moderate and severe attacks which 
cannot be prevented with nonspecific migraine drugs 
are managed with specific drugs such as triptans or 
ergot derivatives.(5) 
Although the central effects of NSAIDs are not exactly 
known, three mechanisms are mainly emphasized. 
These are the inhibition of central nervous system 
prostaglandin synthesis by NSAIDs, the increasing of 
CNS catecholamine and serotonin cycle, and the 
inhibition of serotonin release during pain stimulus. (6)  
Lornoxicam (LNX) (6-chloro-4-hydroxy 2-methyl 
N-pyridyl 2H-thienol (2, 3 e) 1, 2-thiazine 
2-karbaksamid 1, 1-dioxide), is a NSAID drug in 
non-selective, oxicam group according to former 
classification. LNX has potent anti-inflammatory and 
analgesic effects similar to other oxicams but unlike 
them it has a shorter half life (3-5 hours). Both oral and 
parenteral preparations are used. LNX has a better 
tolerability profile compared with other oxicam drugs 
because of shorter half life. (7) Clinical trials suggest LNX 
as an effective drug in the treatment of post-operative 
and joint pains. The aim of this study was to assess the 
efficacy of LNX in treatment of headaches due to acute 
migraine attacks. 
 
MATERIAL AND METHODS 
 
This is a prospective, randomized, double-blind, 
placebo-controlled study conducted by department of 
clinical of algology, school of medicine Istanbul 
University and department of neurology, Ministry of 
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Health Dr. Sadi Konuk Research and Training Hospital 
between January 2010 and December 2012. Inclusion 
criteria was:  
- age between 18 and 65 years,  
- being diagnosed with migraine without aura 
 according to the International Headache 
 Society   criteria (the year 2004), 
- having experience of first headache attack 
 before 50 years of age,  
- having moderate to severe migraine attacks 
 with frequency less than 4 times per month.
   
This study was approved by ethics committee that was 
established in the School of Medicine, Istanbul 
University. Randomization table has been used for 
randomization of the patients. Diagnosis of migraine of 
the included patients was done by a neurology 
physician. Patients’ migraine attacks were recorded to 
assess the effectiveness of LNX.  After being informed 
about the study, all volunteers were asked to sign the 
"informed consent form". Patients’ physical 
examinations, pulse rates and blood pressure of 
patients as well as medical history regarding usage of 
drug or non-drug medications and simultaneous 
systemic diseases were recorded during all visits. 
Patients who were pregnant, nursing and planning to be 
pregnant during the study, not informed about 
treatment sufficiently, used different treatment for 
migraine attacks, and who quitted the follow-up were 
excluded from the study. Patients received two different 
blisters containing either placebo or the study drug (8 
mg LNX) for two migraine attacks during first and 
second visits. The 3rd visit was arranged at the end of 
the fourth week or within five days after second attack 
and the 4th visit was arranged at the end of the eighth 
week or within five days after third attack. They were 
allowed to use maximum two tablets in a day. If 
headache persisted despite the use of the two tablets 
given for the study, they were permitted to use 
eletriptan 40 mg as a subsidiary medicine at least an 
hour after the second tablet. Patients were inquired 
which blister they had taken if they had  headache 
attack and whether they had taken one more tablet 
from blisters when headache persisted for three hours. 
Migraine attacks of patients which were not recorded 
during follow up were not evaluated. Pain intensity 
score was rated from 0 to 3 points (0= none, 1= mild, 
2= moderate, 3= severe) in the survey. Headache 
severity was evaluated with a questionnaire performed 
before taking the drug at 0.min and at 15th, 30th, 
60th, 90th minutes and at 2nd, 3th, 6th, 12th, 24th 
hours after the administration of drug. Pain relief was 
assessed with a rating system of 5 points (0= none, 
improvement; 1= a little, 2= some, 3= a lot, 4= 
complete, and worsening; -1= a litte, -2= some, -3= 
a lot, -4= complete) after the administration of drug at 
15 th, 30 th, 60 th, 90 th minutes and at 2 nd, 3 th, 
6 th, 12 th, 24 th hours. Evaluation of patient 
satisfaction was assessed at the end of the 24-h period 
(1= satisfied, 2= unsatisfied). (8)
A Statistical Analysis  
Age was expressed as mean ±standard deviation. 
Changes in headache severity were assessed by 
Mann-Whitney U test in the pre-treatment period and 
after the treatment at 15th, 30th, 60th, 90th minutes 
and 2nd, 3th, 6th, 12th, 24th hours. Characteristics of 
patient and placebo groups and satisfaction with the 
treatment between placebo and treatment group was 
assessed by Chi-square test. Statistical significance 
was determined at p <0.05.
Table 1: Demographic characteristics of the study 
participants.  
RESULTS 
 
During the study period, 6 of 50 patients were excluded 
from the study due to excluding criteria. Of 44 patients 
whose 120 migraine attacks were evaluated, 38 were 
females. Mean age 37.75 ± 9.28 years. 
Characteristics of patients have been shown in Table 1. 
There was no comorbidity in both patient and placebo 
groups. During the study period, LNX was used in the 
87 attacks, placebo was used in the 33 attacks. The 
number of headache attacks in which placebo and LNX 
were used is given in Table 2. 
 
Evaluation of patients’ pain intensity scores 
The severity of the headache was assessed individually 
after administration of the first dose at the beginning, 
15th, 30th, 60th, 90th minutes and the 2nd, 3th, 6th, 
12th, 24th hours in both groups. There was not found 
difference between pain intensity scores which were 
surveyed after LNX and placebo treatments, statistically 
(Table 3). 
Evaluation of patients’ pain relief scores 
The pain relief was assessed individually after 
administration of the first dose at 15th, 30th, 60th, 
90th minutes and the 2nd, 3th, 6th, 12th, 24th hours 
in both groups. There was not found any difference 
between pain intensity scores which were surveyed after 
LNX and placebo treatments, statistically (Table 4).
Evaluation of patients’ satisfaction scores 
Patients’ satisfaction scores were insignificant between 
LNX and placebo treatments, statistically (Table 5). 
Evaluation of drug associated side-effects 
No adverse reactions were with both placebo treatment 
and LNX treatment.   
Table 2: Distribution of the number of migraine attacks 
in which LNX and placebo treatments were given 
 
DISCUSSION 
 
LNX has been evaluated for the first time in terms of its 
efficacy and side-effects, due to the fact that there has 
been no study about it in the treatment of acute 
migraine attacks. In context with that although NSAIDs 
were presented to be effective in the treatment of acute 
migraine attacks, serum level concentration of LNX 
should be measured after oral use to evaluate the 
efficacy appropriately. (5) Since oral usage of LNX cannot 
reach therapeutic blood concentration rapidly and 
sufficiently despite its short and rapid time of action, 
because of first-pass elimination. Also a parenteral form 
of LNX may be evaluated or compared with oral form to 
reveal its effectiveness and whether the administration 
route is important or not. Despite studies showing the 
effectiveness of oral administration of LNX’ are 
associated with pains other than migraine it is 
important to ensure early, rapid and effective plasma 
concentration in pains related to migraine. (9, 10)  NSAIDs 
in the oxicam groups were reported to be effective for 
acute migraine attacks. In a study conducted by CY et 
al the effectiveness of celecoxib and naproxen sodium 
in the treatment of acute migraine was investigated. 
Both drugs were found to be equally effective in the 
treatment of acute migraine, but epigastric pain was 
found significantly higher in the naproxen sodium 
group. (11) Ravishankar and colleagues evaluated the 
efficacy of sublingual piroxicam in patients suffering 
from migraine without aura. In their study, either 
piroxicam 40 mg or placebo was administered 
randomly and double-blind to 60 patients who were 
suffering from two to 16 migraine attacks per month 
without aura at age 18-50 years. (12) The severity of the 
pain was evaluated using the visual analogue scale 
(VAS). This study described the decrease in pain 
intensity at 15 min and even 24 hours after sublingual 
piroxicam administration. This decrease was 
statistically significant compared to placebo (12) 
Ravishankar and his colleagues administered placebo 
and the drug in different patient groups, whereas drug 
and placebo were administered to the same group of 
patients in our study. The small population size and 
administration of both the drug and placebo into a 
group of patients are likely to be related to this 
insignificance. Although mean age and the number of 
migraine attacks in our study were similar to 
Ravinshankar’s study, sublingual form is likely to cause 
to different results compared to oral form as well. Since 
the administration of piroxicam sublingually reaches an 
effective blood plasma concentration without being 
exposed to the first-pass elimination in the liver. The 
side - effect did not develop in our study. In a study 
comparing of LNX with intravenous morphine in the 
treatment of post operative pain, LNX was found to 
provide similar analgesic effect with a lower incidence 
of adverse events. (10) Adverse effects, such as nausea, 
vomiting, gastritis, heartburn, and diarrhea were 
reported to develop less with a sublingual form of LNX 
than naproxen sodium in the study of Aabakken et al. (9) 
In a study performed on healthy volunteers, it has been 
verified that less gastro-duodenal injury developed with 
LNX (16 mg / day) compared to naproxen sodium 
(1000 mg / day). (9) The limitations of our study are 
small population size, administration of both drug and 
placebo in some cases, usage of only oral form of LNX. 
Intravenous form of LNX should be evaluated in terms of 
efficacy and side-effects compared with oral forms of 
LNX with a randomized-controlled study for treatment of 
acute migraine attacks. As a result, although oral LNX 
was found to have efficacy similar to placebo 
statistically in the treatment of acute migraine attacks, 
further studies are needed, including two different 
groups, two forms and different dosages of LNX to 
evaluate appropriately the efficacy of LNX for treatment 
of acute migraine attacks.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION 
 
Migraine is a common cause of headache. Prevalence 
of migraine is reported to be 11% in the adult 
population in the studies from western countries. (1)  The 
study, which was conducted by Turkish headache 
epidemiology study group reported the incidence of 
migraine to be 16.4% between 15-65 years old. (2) It is 
seen three times more in women than men, and it often 
occurs between the ages of 25 to 55 years. (3, 4) 
Migraine treatments are generally based on two major 
groups, including non-pharmacological and pharmacol- 
ogical methods. Pharmacological treatment is divided 
into two groups; prophylactic and acute attack 
treatment.(5) Acute migraine attacks should be managed 
rapidly and effectively. Therapy is considered to be 
successful when there is decrease in the frequency and 
severity of attacks.(5) Acute attack treatment should be 
tailored to the patients systemic disease and symptoms 
as well as the severity, duration and frequency of the 
attacks. In mild and moderate attacks, non-specific 
therapy non-steroidal anti-inflammatory drugs (NSAIDs) 
alone or in combination with either caffeine or codeine 
may be used. Moderate and severe attacks which 
cannot be prevented with nonspecific migraine drugs 
are managed with specific drugs such as triptans or 
ergot derivatives.(5) 
Although the central effects of NSAIDs are not exactly 
known, three mechanisms are mainly emphasized. 
These are the inhibition of central nervous system 
prostaglandin synthesis by NSAIDs, the increasing of 
CNS catecholamine and serotonin cycle, and the 
inhibition of serotonin release during pain stimulus. (6)  
Lornoxicam (LNX) (6-chloro-4-hydroxy 2-methyl 
N-pyridyl 2H-thienol (2, 3 e) 1, 2-thiazine 
2-karbaksamid 1, 1-dioxide), is a NSAID drug in 
non-selective, oxicam group according to former 
classification. LNX has potent anti-inflammatory and 
analgesic effects similar to other oxicams but unlike 
them it has a shorter half life (3-5 hours). Both oral and 
parenteral preparations are used. LNX has a better 
tolerability profile compared with other oxicam drugs 
because of shorter half life. (7) Clinical trials suggest LNX 
as an effective drug in the treatment of post-operative 
and joint pains. The aim of this study was to assess the 
efficacy of LNX in treatment of headaches due to acute 
migraine attacks. 
 
MATERIAL AND METHODS 
 
This is a prospective, randomized, double-blind, 
placebo-controlled study conducted by department of 
clinical of algology, school of medicine Istanbul 
University and department of neurology, Ministry of 
Health Dr. Sadi Konuk Research and Training Hospital 
between January 2010 and December 2012. Inclusion 
criteria was:  
- age between 18 and 65 years,  
- being diagnosed with migraine without aura 
 according to the International Headache 
 Society   criteria (the year 2004), 
- having experience of first headache attack 
 before 50 years of age,  
- having moderate to severe migraine attacks 
 with frequency less than 4 times per month.
   
This study was approved by ethics committee that was 
established in the School of Medicine, Istanbul 
University. Randomization table has been used for 
randomization of the patients. Diagnosis of migraine of 
the included patients was done by a neurology 
physician. Patients’ migraine attacks were recorded to 
assess the effectiveness of LNX.  After being informed 
about the study, all volunteers were asked to sign the 
"informed consent form". Patients’ physical 
examinations, pulse rates and blood pressure of 
patients as well as medical history regarding usage of 
drug or non-drug medications and simultaneous 
systemic diseases were recorded during all visits. 
Patients who were pregnant, nursing and planning to be 
pregnant during the study, not informed about 
treatment sufficiently, used different treatment for 
migraine attacks, and who quitted the follow-up were 
excluded from the study. Patients received two different 
blisters containing either placebo or the study drug (8 
mg LNX) for two migraine attacks during first and 
second visits. The 3rd visit was arranged at the end of 
the fourth week or within five days after second attack 
and the 4th visit was arranged at the end of the eighth 
week or within five days after third attack. They were 
allowed to use maximum two tablets in a day. If 
headache persisted despite the use of the two tablets 
given for the study, they were permitted to use 
eletriptan 40 mg as a subsidiary medicine at least an 
hour after the second tablet. Patients were inquired 
which blister they had taken if they had  headache 
attack and whether they had taken one more tablet 
from blisters when headache persisted for three hours. 
Migraine attacks of patients which were not recorded 
during follow up were not evaluated. Pain intensity 
score was rated from 0 to 3 points (0= none, 1= mild, 
2= moderate, 3= severe) in the survey. Headache 
severity was evaluated with a questionnaire performed 
before taking the drug at 0.min and at 15th, 30th, 
60th, 90th minutes and at 2nd, 3th, 6th, 12th, 24th 
hours after the administration of drug. Pain relief was 
assessed with a rating system of 5 points (0= none, 
improvement; 1= a little, 2= some, 3= a lot, 4= 
complete, and worsening; -1= a litte, -2= some, -3= 
a lot, -4= complete) after the administration of drug at 
15 th, 30 th, 60 th, 90 th minutes and at 2 nd, 3 th, 
6 th, 12 th, 24 th hours. Evaluation of patient 
satisfaction was assessed at the end of the 24-h period 
(1= satisfied, 2= unsatisfied). (8)
A Statistical Analysis  
Age was expressed as mean ±standard deviation. 
Changes in headache severity were assessed by 
Mann-Whitney U test in the pre-treatment period and 
after the treatment at 15th, 30th, 60th, 90th minutes 
and 2nd, 3th, 6th, 12th, 24th hours. Characteristics of 
patient and placebo groups and satisfaction with the 
treatment between placebo and treatment group was 
assessed by Chi-square test. Statistical significance 
was determined at p <0.05.
Table 1: Demographic characteristics of the study 
participants.  
RESULTS 
 
During the study period, 6 of 50 patients were excluded 
from the study due to excluding criteria. Of 44 patients 
whose 120 migraine attacks were evaluated, 38 were 
females. Mean age 37.75 ± 9.28 years. 
Characteristics of patients have been shown in Table 1. 
There was no comorbidity in both patient and placebo 
groups. During the study period, LNX was used in the 
87 attacks, placebo was used in the 33 attacks. The 
number of headache attacks in which placebo and LNX 
were used is given in Table 2. 
 
Evaluation of patients’ pain intensity scores 
The severity of the headache was assessed individually 
after administration of the first dose at the beginning, 
15th, 30th, 60th, 90th minutes and the 2nd, 3th, 6th, 
12th, 24th hours in both groups. There was not found 
difference between pain intensity scores which were 
surveyed after LNX and placebo treatments, statistically 
(Table 3). 
 Placebo (n=14) LNX (n=30) P
Female/Male 11/3 27/3 0.364
Age (years;  37.9 ± 10.1 37.5 ± 8.4 0.902
mean ± SD)
Illiterate 2 1 
Elementary  10 16
School 
High School - 4 
University 2 9  
   0.902
Evaluation of patients’ pain relief scores 
The pain relief was assessed individually after 
administration of the first dose at 15th, 30th, 60th, 
90th minutes and the 2nd, 3th, 6th, 12th, 24th hours 
in both groups. There was not found any difference 
between pain intensity scores which were surveyed after 
LNX and placebo treatments, statistically (Table 4).
Evaluation of patients’ satisfaction scores 
Patients’ satisfaction scores were insignificant between 
LNX and placebo treatments, statistically (Table 5). 
Evaluation of drug associated side-effects 
No adverse reactions were with both placebo treatment 
and LNX treatment.   
Table 2: Distribution of the number of migraine attacks 
in which LNX and placebo treatments were given 
 
DISCUSSION 
 
LNX has been evaluated for the first time in terms of its 
efficacy and side-effects, due to the fact that there has 
been no study about it in the treatment of acute 
migraine attacks. In context with that although NSAIDs 
were presented to be effective in the treatment of acute 
migraine attacks, serum level concentration of LNX 
should be measured after oral use to evaluate the 
efficacy appropriately. (5) Since oral usage of LNX cannot 
reach therapeutic blood concentration rapidly and 
sufficiently despite its short and rapid time of action, 
because of first-pass elimination. Also a parenteral form 
of LNX may be evaluated or compared with oral form to 
reveal its effectiveness and whether the administration 
route is important or not. Despite studies showing the 
effectiveness of oral administration of LNX’ are 
associated with pains other than migraine it is 
important to ensure early, rapid and effective plasma 
concentration in pains related to migraine. (9, 10)  NSAIDs 
in the oxicam groups were reported to be effective for 
acute migraine attacks. In a study conducted by CY et 
al the effectiveness of celecoxib and naproxen sodium 
in the treatment of acute migraine was investigated. 
Both drugs were found to be equally effective in the 
treatment of acute migraine, but epigastric pain was 
found significantly higher in the naproxen sodium 
group. (11) Ravishankar and colleagues evaluated the 
efficacy of sublingual piroxicam in patients suffering 
from migraine without aura. In their study, either 
piroxicam 40 mg or placebo was administered 
randomly and double-blind to 60 patients who were 
suffering from two to 16 migraine attacks per month 
without aura at age 18-50 years. (12) The severity of the 
pain was evaluated using the visual analogue scale 
(VAS). This study described the decrease in pain 
intensity at 15 min and even 24 hours after sublingual 
piroxicam administration. This decrease was 
statistically significant compared to placebo (12) 
Ravishankar and his colleagues administered placebo 
and the drug in different patient groups, whereas drug 
and placebo were administered to the same group of 
patients in our study. The small population size and 
administration of both the drug and placebo into a 
group of patients are likely to be related to this 
insignificance. Although mean age and the number of 
migraine attacks in our study were similar to 
Ravinshankar’s study, sublingual form is likely to cause 
to different results compared to oral form as well. Since 
the administration of piroxicam sublingually reaches an 
effective blood plasma concentration without being 
exposed to the first-pass elimination in the liver. The 
side - effect did not develop in our study. In a study 
comparing of LNX with intravenous morphine in the 
treatment of post operative pain, LNX was found to 
provide similar analgesic effect with a lower incidence 
of adverse events. (10) Adverse effects, such as nausea, 
vomiting, gastritis, heartburn, and diarrhea were 
reported to develop less with a sublingual form of LNX 
than naproxen sodium in the study of Aabakken et al. (9) 
In a study performed on healthy volunteers, it has been 
verified that less gastro-duodenal injury developed with 
LNX (16 mg / day) compared to naproxen sodium 
(1000 mg / day). (9) The limitations of our study are 
small population size, administration of both drug and 
placebo in some cases, usage of only oral form of LNX. 
Intravenous form of LNX should be evaluated in terms of 
efficacy and side-effects compared with oral forms of 
LNX with a randomized-controlled study for treatment of 
acute migraine attacks. As a result, although oral LNX 
was found to have efficacy similar to placebo 
statistically in the treatment of acute migraine attacks, 
further studies are needed, including two different 
groups, two forms and different dosages of LNX to 
evaluate appropriately the efficacy of LNX for treatment 
of acute migraine attacks.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION 
 
Migraine is a common cause of headache. Prevalence 
of migraine is reported to be 11% in the adult 
population in the studies from western countries. (1)  The 
study, which was conducted by Turkish headache 
epidemiology study group reported the incidence of 
migraine to be 16.4% between 15-65 years old. (2) It is 
seen three times more in women than men, and it often 
occurs between the ages of 25 to 55 years. (3, 4) 
Migraine treatments are generally based on two major 
groups, including non-pharmacological and pharmacol- 
ogical methods. Pharmacological treatment is divided 
into two groups; prophylactic and acute attack 
treatment.(5) Acute migraine attacks should be managed 
rapidly and effectively. Therapy is considered to be 
successful when there is decrease in the frequency and 
severity of attacks.(5) Acute attack treatment should be 
tailored to the patients systemic disease and symptoms 
as well as the severity, duration and frequency of the 
attacks. In mild and moderate attacks, non-specific 
therapy non-steroidal anti-inflammatory drugs (NSAIDs) 
alone or in combination with either caffeine or codeine 
may be used. Moderate and severe attacks which 
cannot be prevented with nonspecific migraine drugs 
are managed with specific drugs such as triptans or 
ergot derivatives.(5) 
Although the central effects of NSAIDs are not exactly 
known, three mechanisms are mainly emphasized. 
These are the inhibition of central nervous system 
prostaglandin synthesis by NSAIDs, the increasing of 
CNS catecholamine and serotonin cycle, and the 
inhibition of serotonin release during pain stimulus. (6)  
Lornoxicam (LNX) (6-chloro-4-hydroxy 2-methyl 
N-pyridyl 2H-thienol (2, 3 e) 1, 2-thiazine 
2-karbaksamid 1, 1-dioxide), is a NSAID drug in 
non-selective, oxicam group according to former 
classification. LNX has potent anti-inflammatory and 
analgesic effects similar to other oxicams but unlike 
them it has a shorter half life (3-5 hours). Both oral and 
parenteral preparations are used. LNX has a better 
tolerability profile compared with other oxicam drugs 
because of shorter half life. (7) Clinical trials suggest LNX 
as an effective drug in the treatment of post-operative 
and joint pains. The aim of this study was to assess the 
efficacy of LNX in treatment of headaches due to acute 
migraine attacks. 
 
MATERIAL AND METHODS 
 
This is a prospective, randomized, double-blind, 
placebo-controlled study conducted by department of 
clinical of algology, school of medicine Istanbul 
University and department of neurology, Ministry of 
Health Dr. Sadi Konuk Research and Training Hospital 
between January 2010 and December 2012. Inclusion 
criteria was:  
- age between 18 and 65 years,  
- being diagnosed with migraine without aura 
 according to the International Headache 
 Society   criteria (the year 2004), 
- having experience of first headache attack 
 before 50 years of age,  
- having moderate to severe migraine attacks 
 with frequency less than 4 times per month.
   
This study was approved by ethics committee that was 
established in the School of Medicine, Istanbul 
University. Randomization table has been used for 
randomization of the patients. Diagnosis of migraine of 
the included patients was done by a neurology 
physician. Patients’ migraine attacks were recorded to 
assess the effectiveness of LNX.  After being informed 
about the study, all volunteers were asked to sign the 
"informed consent form". Patients’ physical 
examinations, pulse rates and blood pressure of 
patients as well as medical history regarding usage of 
drug or non-drug medications and simultaneous 
systemic diseases were recorded during all visits. 
Patients who were pregnant, nursing and planning to be 
pregnant during the study, not informed about 
treatment sufficiently, used different treatment for 
migraine attacks, and who quitted the follow-up were 
excluded from the study. Patients received two different 
blisters containing either placebo or the study drug (8 
mg LNX) for two migraine attacks during first and 
second visits. The 3rd visit was arranged at the end of 
the fourth week or within five days after second attack 
and the 4th visit was arranged at the end of the eighth 
week or within five days after third attack. They were 
allowed to use maximum two tablets in a day. If 
headache persisted despite the use of the two tablets 
given for the study, they were permitted to use 
eletriptan 40 mg as a subsidiary medicine at least an 
hour after the second tablet. Patients were inquired 
which blister they had taken if they had  headache 
attack and whether they had taken one more tablet 
from blisters when headache persisted for three hours. 
Migraine attacks of patients which were not recorded 
during follow up were not evaluated. Pain intensity 
score was rated from 0 to 3 points (0= none, 1= mild, 
2= moderate, 3= severe) in the survey. Headache 
severity was evaluated with a questionnaire performed 
before taking the drug at 0.min and at 15th, 30th, 
60th, 90th minutes and at 2nd, 3th, 6th, 12th, 24th 
hours after the administration of drug. Pain relief was 
assessed with a rating system of 5 points (0= none, 
improvement; 1= a little, 2= some, 3= a lot, 4= 
complete, and worsening; -1= a litte, -2= some, -3= 
a lot, -4= complete) after the administration of drug at 
15 th, 30 th, 60 th, 90 th minutes and at 2 nd, 3 th, 
6 th, 12 th, 24 th hours. Evaluation of patient 
satisfaction was assessed at the end of the 24-h period 
(1= satisfied, 2= unsatisfied). (8)
A Statistical Analysis  
Age was expressed as mean ±standard deviation. 
Changes in headache severity were assessed by 
Mann-Whitney U test in the pre-treatment period and 
after the treatment at 15th, 30th, 60th, 90th minutes 
and 2nd, 3th, 6th, 12th, 24th hours. Characteristics of 
patient and placebo groups and satisfaction with the 
treatment between placebo and treatment group was 
assessed by Chi-square test. Statistical significance 
was determined at p <0.05.
Table 1: Demographic characteristics of the study 
participants.  
RESULTS 
 
During the study period, 6 of 50 patients were excluded 
from the study due to excluding criteria. Of 44 patients 
whose 120 migraine attacks were evaluated, 38 were 
females. Mean age 37.75 ± 9.28 years. 
Characteristics of patients have been shown in Table 1. 
There was no comorbidity in both patient and placebo 
groups. During the study period, LNX was used in the 
87 attacks, placebo was used in the 33 attacks. The 
number of headache attacks in which placebo and LNX 
were used is given in Table 2. 
 
Evaluation of patients’ pain intensity scores 
The severity of the headache was assessed individually 
after administration of the first dose at the beginning, 
15th, 30th, 60th, 90th minutes and the 2nd, 3th, 6th, 
12th, 24th hours in both groups. There was not found 
difference between pain intensity scores which were 
surveyed after LNX and placebo treatments, statistically 
(Table 3). 
Evaluation of patients’ pain relief scores 
The pain relief was assessed individually after 
administration of the first dose at 15th, 30th, 60th, 
90th minutes and the 2nd, 3th, 6th, 12th, 24th hours 
in both groups. There was not found any difference 
between pain intensity scores which were surveyed after 
LNX and placebo treatments, statistically (Table 4).
Evaluation of patients’ satisfaction scores 
Patients’ satisfaction scores were insignificant between 
LNX and placebo treatments, statistically (Table 5). 
Evaluation of drug associated side-effects 
No adverse reactions were with both placebo treatment 
and LNX treatment.   
Table 2: Distribution of the number of migraine attacks 
in which LNX and placebo treatments were given 
 
DISCUSSION 
 
LNX has been evaluated for the first time in terms of its 
efficacy and side-effects, due to the fact that there has 
been no study about it in the treatment of acute 
migraine attacks. In context with that although NSAIDs 
were presented to be effective in the treatment of acute 
migraine attacks, serum level concentration of LNX 
should be measured after oral use to evaluate the 
efficacy appropriately. (5) Since oral usage of LNX cannot 
reach therapeutic blood concentration rapidly and 
sufficiently despite its short and rapid time of action, 
because of first-pass elimination. Also a parenteral form 
of LNX may be evaluated or compared with oral form to 
reveal its effectiveness and whether the administration 
route is important or not. Despite studies showing the 
effectiveness of oral administration of LNX’ are 
associated with pains other than migraine it is 
important to ensure early, rapid and effective plasma 
concentration in pains related to migraine. (9, 10)  NSAIDs 
in the oxicam groups were reported to be effective for 
acute migraine attacks. In a study conducted by CY et 
al the effectiveness of celecoxib and naproxen sodium 
in the treatment of acute migraine was investigated. 
Both drugs were found to be equally effective in the 
treatment of acute migraine, but epigastric pain was 
found significantly higher in the naproxen sodium 
group. (11) Ravishankar and colleagues evaluated the 
efficacy of sublingual piroxicam in patients suffering 
from migraine without aura. In their study, either 
piroxicam 40 mg or placebo was administered 
randomly and double-blind to 60 patients who were 
suffering from two to 16 migraine attacks per month 
without aura at age 18-50 years. (12) The severity of the 
pain was evaluated using the visual analogue scale 
(VAS). This study described the decrease in pain 
intensity at 15 min and even 24 hours after sublingual 
piroxicam administration. This decrease was 
statistically significant compared to placebo (12) 
Ravishankar and his colleagues administered placebo 
and the drug in different patient groups, whereas drug 
and placebo were administered to the same group of 
patients in our study. The small population size and 
administration of both the drug and placebo into a 
group of patients are likely to be related to this 
insignificance. Although mean age and the number of 
migraine attacks in our study were similar to 
Ravinshankar’s study, sublingual form is likely to cause 
to different results compared to oral form as well. Since 
the administration of piroxicam sublingually reaches an 
effective blood plasma concentration without being 
exposed to the first-pass elimination in the liver. The 
side - effect did not develop in our study. In a study 
comparing of LNX with intravenous morphine in the 
treatment of post operative pain, LNX was found to 
provide similar analgesic effect with a lower incidence 
of adverse events. (10) Adverse effects, such as nausea, 
vomiting, gastritis, heartburn, and diarrhea were 
reported to develop less with a sublingual form of LNX 
than naproxen sodium in the study of Aabakken et al. (9) 
In a study performed on healthy volunteers, it has been 
verified that less gastro-duodenal injury developed with 
LNX (16 mg / day) compared to naproxen sodium 
(1000 mg / day). (9) The limitations of our study are 
small population size, administration of both drug and 
placebo in some cases, usage of only oral form of LNX. 
Intravenous form of LNX should be evaluated in terms of 
efficacy and side-effects compared with oral forms of 
LNX with a randomized-controlled study for treatment of 
acute migraine attacks. As a result, although oral LNX 
was found to have efficacy similar to placebo 
statistically in the treatment of acute migraine attacks, 
further studies are needed, including two different 
groups, two forms and different dosages of LNX to 
evaluate appropriately the efficacy of LNX for treatment 
of acute migraine attacks.
 Placebo  LNX   p
The number  n %  n  % 
of migraine 
attacks  
1  13  39.4  29  33.3  
2  8  24.2  20  23  
3  5  15.2  26  29.9  
4  7  21.2  12  13.8  
Total  33  100  87  100  0.360
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION 
 
Migraine is a common cause of headache. Prevalence 
of migraine is reported to be 11% in the adult 
population in the studies from western countries. (1)  The 
study, which was conducted by Turkish headache 
epidemiology study group reported the incidence of 
migraine to be 16.4% between 15-65 years old. (2) It is 
seen three times more in women than men, and it often 
occurs between the ages of 25 to 55 years. (3, 4) 
Migraine treatments are generally based on two major 
groups, including non-pharmacological and pharmacol- 
ogical methods. Pharmacological treatment is divided 
into two groups; prophylactic and acute attack 
treatment.(5) Acute migraine attacks should be managed 
rapidly and effectively. Therapy is considered to be 
successful when there is decrease in the frequency and 
severity of attacks.(5) Acute attack treatment should be 
tailored to the patients systemic disease and symptoms 
as well as the severity, duration and frequency of the 
attacks. In mild and moderate attacks, non-specific 
therapy non-steroidal anti-inflammatory drugs (NSAIDs) 
alone or in combination with either caffeine or codeine 
may be used. Moderate and severe attacks which 
cannot be prevented with nonspecific migraine drugs 
are managed with specific drugs such as triptans or 
ergot derivatives.(5) 
Although the central effects of NSAIDs are not exactly 
known, three mechanisms are mainly emphasized. 
These are the inhibition of central nervous system 
prostaglandin synthesis by NSAIDs, the increasing of 
CNS catecholamine and serotonin cycle, and the 
inhibition of serotonin release during pain stimulus. (6)  
Lornoxicam (LNX) (6-chloro-4-hydroxy 2-methyl 
N-pyridyl 2H-thienol (2, 3 e) 1, 2-thiazine 
2-karbaksamid 1, 1-dioxide), is a NSAID drug in 
non-selective, oxicam group according to former 
classification. LNX has potent anti-inflammatory and 
analgesic effects similar to other oxicams but unlike 
them it has a shorter half life (3-5 hours). Both oral and 
parenteral preparations are used. LNX has a better 
tolerability profile compared with other oxicam drugs 
because of shorter half life. (7) Clinical trials suggest LNX 
as an effective drug in the treatment of post-operative 
and joint pains. The aim of this study was to assess the 
efficacy of LNX in treatment of headaches due to acute 
migraine attacks. 
 
MATERIAL AND METHODS 
 
This is a prospective, randomized, double-blind, 
placebo-controlled study conducted by department of 
clinical of algology, school of medicine Istanbul 
University and department of neurology, Ministry of 
Health Dr. Sadi Konuk Research and Training Hospital 
between January 2010 and December 2012. Inclusion 
criteria was:  
- age between 18 and 65 years,  
- being diagnosed with migraine without aura 
 according to the International Headache 
 Society   criteria (the year 2004), 
- having experience of first headache attack 
 before 50 years of age,  
- having moderate to severe migraine attacks 
 with frequency less than 4 times per month.
   
This study was approved by ethics committee that was 
established in the School of Medicine, Istanbul 
University. Randomization table has been used for 
randomization of the patients. Diagnosis of migraine of 
the included patients was done by a neurology 
physician. Patients’ migraine attacks were recorded to 
assess the effectiveness of LNX.  After being informed 
about the study, all volunteers were asked to sign the 
"informed consent form". Patients’ physical 
examinations, pulse rates and blood pressure of 
patients as well as medical history regarding usage of 
drug or non-drug medications and simultaneous 
systemic diseases were recorded during all visits. 
Patients who were pregnant, nursing and planning to be 
pregnant during the study, not informed about 
treatment sufficiently, used different treatment for 
migraine attacks, and who quitted the follow-up were 
excluded from the study. Patients received two different 
blisters containing either placebo or the study drug (8 
mg LNX) for two migraine attacks during first and 
second visits. The 3rd visit was arranged at the end of 
the fourth week or within five days after second attack 
and the 4th visit was arranged at the end of the eighth 
week or within five days after third attack. They were 
allowed to use maximum two tablets in a day. If 
headache persisted despite the use of the two tablets 
given for the study, they were permitted to use 
eletriptan 40 mg as a subsidiary medicine at least an 
hour after the second tablet. Patients were inquired 
which blister they had taken if they had  headache 
attack and whether they had taken one more tablet 
from blisters when headache persisted for three hours. 
Migraine attacks of patients which were not recorded 
during follow up were not evaluated. Pain intensity 
score was rated from 0 to 3 points (0= none, 1= mild, 
2= moderate, 3= severe) in the survey. Headache 
severity was evaluated with a questionnaire performed 
before taking the drug at 0.min and at 15th, 30th, 
60th, 90th minutes and at 2nd, 3th, 6th, 12th, 24th 
hours after the administration of drug. Pain relief was 
assessed with a rating system of 5 points (0= none, 
improvement; 1= a little, 2= some, 3= a lot, 4= 
complete, and worsening; -1= a litte, -2= some, -3= 
a lot, -4= complete) after the administration of drug at 
15 th, 30 th, 60 th, 90 th minutes and at 2 nd, 3 th, 
6 th, 12 th, 24 th hours. Evaluation of patient 
satisfaction was assessed at the end of the 24-h period 
(1= satisfied, 2= unsatisfied). (8)
A Statistical Analysis  
Age was expressed as mean ±standard deviation. 
Changes in headache severity were assessed by 
Mann-Whitney U test in the pre-treatment period and 
after the treatment at 15th, 30th, 60th, 90th minutes 
and 2nd, 3th, 6th, 12th, 24th hours. Characteristics of 
patient and placebo groups and satisfaction with the 
treatment between placebo and treatment group was 
assessed by Chi-square test. Statistical significance 
was determined at p <0.05.
Table 1: Demographic characteristics of the study 
participants.  
RESULTS 
 
During the study period, 6 of 50 patients were excluded 
from the study due to excluding criteria. Of 44 patients 
whose 120 migraine attacks were evaluated, 38 were 
females. Mean age 37.75 ± 9.28 years. 
Characteristics of patients have been shown in Table 1. 
There was no comorbidity in both patient and placebo 
groups. During the study period, LNX was used in the 
87 attacks, placebo was used in the 33 attacks. The 
number of headache attacks in which placebo and LNX 
were used is given in Table 2. 
 
Evaluation of patients’ pain intensity scores 
The severity of the headache was assessed individually 
after administration of the first dose at the beginning, 
15th, 30th, 60th, 90th minutes and the 2nd, 3th, 6th, 
12th, 24th hours in both groups. There was not found 
difference between pain intensity scores which were 
surveyed after LNX and placebo treatments, statistically 
(Table 3). 
Evaluation of patients’ pain relief scores 
The pain relief was assessed individually after 
administration of the first dose at 15th, 30th, 60th, 
90th minutes and the 2nd, 3th, 6th, 12th, 24th hours 
in both groups. There was not found any difference 
between pain intensity scores which were surveyed after 
LNX and placebo treatments, statistically (Table 4).
Evaluation of patients’ satisfaction scores 
Patients’ satisfaction scores were insignificant between 
LNX and placebo treatments, statistically (Table 5). 
Evaluation of drug associated side-effects 
No adverse reactions were with both placebo treatment 
and LNX treatment.   
Table 2: Distribution of the number of migraine attacks 
in which LNX and placebo treatments were given 
 
DISCUSSION 
 
LNX has been evaluated for the first time in terms of its 
efficacy and side-effects, due to the fact that there has 
been no study about it in the treatment of acute 
migraine attacks. In context with that although NSAIDs 
were presented to be effective in the treatment of acute 
migraine attacks, serum level concentration of LNX 
should be measured after oral use to evaluate the 
efficacy appropriately. (5) Since oral usage of LNX cannot 
reach therapeutic blood concentration rapidly and 
sufficiently despite its short and rapid time of action, 
because of first-pass elimination. Also a parenteral form 
of LNX may be evaluated or compared with oral form to 
reveal its effectiveness and whether the administration 
route is important or not. Despite studies showing the 
effectiveness of oral administration of LNX’ are 
associated with pains other than migraine it is 
important to ensure early, rapid and effective plasma 
concentration in pains related to migraine. (9, 10)  NSAIDs 
in the oxicam groups were reported to be effective for 
acute migraine attacks. In a study conducted by CY et 
al the effectiveness of celecoxib and naproxen sodium 
in the treatment of acute migraine was investigated. 
Both drugs were found to be equally effective in the 
treatment of acute migraine, but epigastric pain was 
found significantly higher in the naproxen sodium 
group. (11) Ravishankar and colleagues evaluated the 
efficacy of sublingual piroxicam in patients suffering 
from migraine without aura. In their study, either 
piroxicam 40 mg or placebo was administered 
randomly and double-blind to 60 patients who were 
suffering from two to 16 migraine attacks per month 
without aura at age 18-50 years. (12) The severity of the 
pain was evaluated using the visual analogue scale 
(VAS). This study described the decrease in pain 
intensity at 15 min and even 24 hours after sublingual 
piroxicam administration. This decrease was 
statistically significant compared to placebo (12) 
Ravishankar and his colleagues administered placebo 
and the drug in different patient groups, whereas drug 
and placebo were administered to the same group of 
patients in our study. The small population size and 
administration of both the drug and placebo into a 
group of patients are likely to be related to this 
insignificance. Although mean age and the number of 
migraine attacks in our study were similar to 
Ravinshankar’s study, sublingual form is likely to cause 
to different results compared to oral form as well. Since 
the administration of piroxicam sublingually reaches an 
effective blood plasma concentration without being 
exposed to the first-pass elimination in the liver. The 
side - effect did not develop in our study. In a study 
comparing of LNX with intravenous morphine in the 
treatment of post operative pain, LNX was found to 
provide similar analgesic effect with a lower incidence 
of adverse events. (10) Adverse effects, such as nausea, 
vomiting, gastritis, heartburn, and diarrhea were 
reported to develop less with a sublingual form of LNX 
than naproxen sodium in the study of Aabakken et al. (9) 
In a study performed on healthy volunteers, it has been 
verified that less gastro-duodenal injury developed with 
LNX (16 mg / day) compared to naproxen sodium 
(1000 mg / day). (9) The limitations of our study are 
small population size, administration of both drug and 
placebo in some cases, usage of only oral form of LNX. 
Intravenous form of LNX should be evaluated in terms of 
efficacy and side-effects compared with oral forms of 
LNX with a randomized-controlled study for treatment of 
acute migraine attacks. As a result, although oral LNX 
was found to have efficacy similar to placebo 
statistically in the treatment of acute migraine attacks, 
further studies are needed, including two different 
groups, two forms and different dosages of LNX to 
evaluate appropriately the efficacy of LNX for treatment 
of acute migraine attacks.
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Table 3: Evaluation of patients’ pain intensity scores after LNX and placebo treatments 
Table 4: The pain relief scores of the cases after LNX and placebo treatments 
 Pain Beginning 15-min   30-min 60-min  90-min  2-h   3-h   6-h   12- h   24-h  
 intensity n (%)  n (%)  n (%) n (%) n (%) n (%) n  (%)  n (%)  n (%)  n (%) 
 score                         
Placebo  0   - -  1(3.1)  2(6.3)  3(10.7)  2(6.7)  2(8.3)  3(37.5)  2(33.3)  3(50) 
Group 1  4(12.1)  5(15.6)  7(21.9)  9(28.1)  7(25)  5(16.7)  8(33.3)  3(37.5)  3(50)  3(50) 
 2  16(48.5)  17(53.1)  16(50)  13(40.6)  11(39.3)  12(40)  8(33.3)  1(12.5)  1(16.7)  - 
 3  13(39.4)  10(31.3)  8(25)  8(25)  7(25)  11(36.6)  6(25.1)  1(12.5)   - - 
LNX 0  -  -  2(2.4)  8(10.1)  4(6)  7(9.3)  13(22.1)  14(42.4)  15(53.6)  13(52) 
Group  1  13(14.9)  12(14.5)  17(20.5)  19(24.1)  21(31.8)  20(26.7)  14(23.7)  6(18.2)  8(28.6)  6(24) 
 2  44(50.6)  38(45.8)  32(38.5)  29(36.7)  23(34.9)  26(34.7)  18(30.5)  9(27.3)  2(7.1)  2(8) 
 3  30(34.5)  33(39.7)  32(38.6)  23(29.1)  18(27.3)  22(29.3)  14(23.7)  4(12.1)  3(10.7)  4(16)
Post-treatment 
 Pain relief 15 min  30 min  60 min  90 min 2 h 3 h 6 h 12 h 24 h
 score n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Placebo 4 - - - - - - - - -
Treatment 3  - 1(3.1)  - - - - 1(12.5)  - 1(16.7) 
 2  1(3.1)  2(6.3)  4(12.5)  5(17.9)  3(10)  6(25)  1(12.5)  3(50)  2(33.3) 
 1  4(12.5)  5(15.6)  8(25)  8(28.5)  9(30)  5(20.8)  5(62.5)  2(33.3)  3(50) 
 0  25(78.1)  22(68.7)  17(53.1)  12(42.9)  12(40)  10(41.7)    - 1(16.7)   -
 -1  2(6.3)  2(6.3)  3(9.4)  3(10.7)  5(16.7)  3(12.5)  1(12.5)   -  -
 -2   -  -  -  - 1(3.3)   -  -  -  -
 -3 - - - - - - - - -
 -4 - - - - - - - - - 
LNX 4 - - - - - - - - -
Treatment 3  - - 2(2.5)  2(3)  2(2.7)  5(8.5)  6(18.2)  6(21.4)  6(24) 
 2  1(1.2)  4(4.8)  6(7.6)  5(7.6)  9(12)  11(18.6)  9(27.3)  11(39.3)  9(36) 
 1  5(6)  11(13.3)  23(29.1)  21(31.8)  18(24)  12(20.3)  6(18.2)  6(21.4)  4(16) 
  0  66(79.5)  54(65)  36(45.6)  27(40.9)  33(44)  20(33.9)  9(27.3)  3(10.7)  4(16) 
 -1  11(13.3)  13(15.7)  11(13.9)  10(15.2)  11(14.6)  10(17)  1(3)  - -
 -2  - 1(1.2)  1(1.3)  1(1.5)  2(2.7)  1(1.7)  2(6)  2(7.2)  2(8) 
 -3 - - - - - - - - -
 -4 - - - - - - - - -
 p value  0.106  0.135  0.793  0.466  0.811  0.967  0.961  0.522  1
Post-treatment 
 Placebo   LNX  p 
 n  %  n  %  
Satisﬁed  18  54.5  48 55.2 
Unsatisﬁed 15 45.5  39 44.8 
Total  33  100  87  100  0.690
Table 5: Patients’ satisfaction scores
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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